AstraZeneca pulls COVID vaccine from European market
LONDON (AP) — The pharma giant AstraZeneca has requested that the European authorization for its COVID-19 vaccine be pulled, according to the EU medicines regulator.
In an update on the European Medicines Agency’s website Wednesday, the regulator said that the approval for AstraZeneca’s Vaxzevria had been withdrawn “at the request of the marketing authorization holder.”
AstraZeneca’s COVID-19 vaccine was first given the nod by the EMA in January 2021. Within weeks, however, concerns grew about the vaccine’s safety, when dozens of countries suspended the vaccine’s use after unusual but rare blood clots were detected in a small number of immunized people. The EU regulator concluded AstraZeneca’s shot didn’t raise the overall risk of clots, but doubts remained.
Partial results from its first major trial — which Britain used to authorize the vaccine — were clouded by a manufacturing mistake that researchers didn’t immediately acknowledge. Insufficient data about how well the vaccine protected older people led some countries to initially restrict its use to younger populations before reversing course.
Related articles
Jean Smart reveals Harry Styles' cheeky 'hack' for checking into hotels undercover
Jean Smart has revealed that Harry Styles sneakily checks into hotels using the alias 'Deborah Vance2024-05-09Kiwi musicians boycott US festival SXSW due to defence industry sponsors
Photo: Supplied2024-05-09US House passes bill that could ban TikTok nationwide
By David Shepardson for ReutersThe fate of TikTok, used by about 170 million Americans, has become a2024-05-09Interislander ferry upgrade: Finance Minister warns of cost blowout
Photo: RNZ/ Rachel Thomas2024-05-09Shopify's shares tumble on weak outlook after a very strong start to 2024
Shares of Shopify plunged Wednesday after the Canadian company that helps retailers with online sale2024-05-09Bill to Fund US Government Includes Money to Counter China in Pacific
WASHINGTON —U.S. congressional negotiators released a bill Sunday that would fund key parts of the g2024-05-09
atest comment